XRP's market value dropped by nearly $6 billion over seven days, falling 6.61% amid a whale selloff despite a spike in daily transaction volume to almost $50 billion on October 19, 2026. U.S. XRP spot ETFs recorded their first weekly outflow in nearly four months, reversing 13 weeks of inflows, with $1.84 million withdrawn last week. The token recently retested a key support level around $1.30 after a 20% correction over four weeks, and analysts suggest the correction may have ended, signaling a potential rebound. However, sustained recovery depends on renewed demand from U.S. XRP ETFs.
XRP's market value drop is the focus, with Pluang market data as of Oct 19, 2026 19:41 WIB showing a mixed US stock market breadth: 77 of 150 priced US stocks rose while 70 fell. Notable gainers include QCOM at USD 176.53 (+2.57%), NOK at USD 9.36 (+2.41%), and TSM at USD 422.41 (+2.38%). The most notable figure is QCOM's typical hold time on Pluang of 87 days.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
